Implexion Pharma

Implexion Pharma develops innovative strategies to treat selected diseases by targeting gut microbial production of disease-causing substances. Implexion's first drug candidate is developed against the orphan drug-classified disease primary sclerosing cholangitis (PSC). Today there is no medical treatment for PSC and the patient needs liver transplantation to prevent premature death. Implexion's therapies have a unique opportunity to treat patients and prolong life, and we have treatments for several other indications in early pipeline.